SCHEMBL6182530

SCHEMBL6182530

CC(C)CC(NC(=O)c1ccc(NC(=O)NCc2ccccn2)cc1)C(=O)N(C)C#N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.51
CTSB P07858 5/20 0.49
RAB9A P51151 3/20 0.49
KMT2A Q03164 3/20 0.48
CTSL P07711 2/20 0.48
CTSS P25774 2/20 0.48
CTSK P43235 2/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.46
DGAT1 O75907 1/20 0.45
ALOX15 P16050 1/20 0.45
GLA P06280 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182635 0.91 NPC1 (0.57) NPC1L3MBTL1CTSBRAB9AKMT2A
SCHEMBL6183575 0.86 DGAT1 (0.54) NPC1CTSBRAB9ACTSLCTSS
SCHEMBL6182524 0.86 CTSL (0.62) NPC1L3MBTL1CTSBRAB9AKMT2A
SCHEMBL6184394 0.85 NPC1 (0.50) NPC1CTSBRAB9AKMT2ACTSL
SCHEMBL6180825 0.85 CTSB (0.45) CTSBCTSLCTSSCTSKDGAT1
SCHEMBL7044208 0.85 NAMPT (0.63) KMT2A
SCHEMBL6183433 0.84 NPC1 (0.48) NPC1CTSBRAB9AKMT2ACTSL
SCHEMBL6182114 0.84 CTSB (0.58) CTSBCTSLCTSSCTSKDGAT1
SCHEMBL6180969 0.83 KMT2A (0.53) KMT2AMEN1LMNAHTT
SCHEMBL6185987 0.83 CTSB (0.47) NPC1CTSBRAB9AKMT2ACTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 NPC1 545/4885L3MBTL1 2986/4885CTSB 11/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 NPC1 545/4885L3MBTL1 2986/4885CTSB 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.